Advertisement

Randall F. Holcombe, MD, MBA, Named Director of UVM Cancer Center and Chief of Hematology and Oncology


Advertisement
Get Permission

The Robert Larner, MD, College of Medicine at The University of Vermont (UVM), in collaboration with the UVM Health Network and the UVM Medical Center, has announced that Randall F. Holcombe, MD, MBA, has been appointed Director of the UVM Cancer Center and Chief of the Division of Hematology and Oncology in the Department of Medicine. Dr. Holcombe is expected to hold the newly established J. Walter Juckett Chair in Cancer Research. He joins UVM and UVM Health Network from the National Cancer Institute (NCI)-designated University of Hawai’i Cancer Center, where he has served as Director since 2016.

Dr. Holcombe succeeds Richard Galbraith, MD, PhD, and Chris Holmes, MD, PhD, who became Interim Co-Directors of UVM Cancer Center in 2020, with Dr. Holmes also serving as Interim Division Chief of Hematology and Oncology since 2017. Dr. Holcombe will officially begin his tenure at UVM on August 1, 2021.

Randall F. Holcombe, MD, MBA

Randall F. Holcombe, MD, MBA

Dr. Holcombe holds an undergraduate degree from Duke University; a medical degree from the New Jersey Medical School; and an MBA from the Zicklin School of Business at Baruch College, part of the City University of New York system. He completed his postdoctoral clinical and research training at Brigham and Women’s Hospital and Harvard Medical School.

Dr. Holcombe served as Associate Director of Clinical and Translational Research at the Chao Family Comprehensive Cancer Center and as Chief, Division of Hematology-Oncology, at the University of California, Irvine, from 1997 through 2010 and as Deputy Director of The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai from 2010 through 2016. He also served as Director of Clinical Cancer Affairs and Chief Medical Officer–Cancer for the Mount Sinai Health System.

At the University of Hawai’i Cancer Center, Dr. Holcombe led the institution through a successful NCI redesignation and Cancer Center Support Grant renewal in 2017–2018. Under his leadership, the center expanded basic, clinical, and population-based research focused on the etiologies of cancer and on interventions to address cancer health disparities in the multiethnic populations of Hawai’i and the Pacific.

 


Advertisement

Advertisement




Advertisement